Can an ankle cartilage lesion be treated without surgery?

For most patients told they have a cartilage lesion on the talus, the assumption is that surgery follows — an arthroscopy, bone marrow stimulation in theatre, or both. That assumption is no longer universal.

For focal, contained osteochondral lesions of the talus (OLTs), a ChondroFiller injection — delivered under ultrasound guidance as an outpatient procedure — now offers a genuinely non-surgical pathway. There is no general anaesthetic, no operating theatre, and no surgical incision. The collagen scaffold is placed directly into the defect at the point of care and the joint is not opened.

Suitability is the critical variable. Lesion size, whether the defect is well-contained, and prior treatment history all determine whether this route is appropriate. Not every OLT qualifies, and a thorough clinical assessment — including imaging — is needed before the decision is made.

The sections below set out how the injection works, who it is likely to help, and what the current clinical evidence shows.

Why ankle cartilage lesions are hard to treat

The talar dome bears more load per unit area than any other joint surface in the lower limb — a mechanical reality that makes cartilage repair at the ankle uniquely demanding. Tissue that fills a defect adequately in a lower-stress environment may simply not survive the forces concentrated here with every step.

What compounds this is the biology. Ankle cartilage is avascular: it receives nutrients by diffusion rather than direct blood supply. When a lesion forms, the body's spontaneous repair response produces fibrocartilage — a mechanically inferior substitute that lacks the stiffness and resilience of the original hyaline tissue. Over time, that fibrocartilage tends to break down under load, which is why untreated or inadequately treated OLTs so often progress.

Around 83% of these lesions occur on the medial talar dome, and the patients who develop them are disproportionately active adults aged between 20 and 40, typically following an ankle sprain or a series of them. The diagnostic problem is that OLTs mimic persistent ligament injury closely enough to be misread as such — meaning the window for early, conservative intervention is regularly missed before chronic changes set in.

Conservative care does work in roughly 50% of acute, non-displaced cases, with activity modification, bracing, and physiotherapy giving the joint a reasonable chance of settling. For the other half — and particularly for lesions reaching 15 mm in average diameter (approximately 150 mm² on MRI) — the picture changes sharply. At that threshold, standard bone marrow stimulation alone carries a success rate of approximately 3%. That figure is not a reason for pessimism; it is the clinical argument for why a scaffold-based approach addresses a genuine biological gap rather than competing with a technique that already works.

How the ChondroFiller injection works

ChondroFiller is a CE-marked Class III medical device — an injectable type I collagen scaffold, not a stem-cell therapy, a lubricant, or a volumetric filler. Each of those categories works through a different mechanism, and the distinction shapes what patients can reasonably expect from treatment.

The product is supplied in a two-chamber syringe. The two components remain separate until they reach the defect site, at which point they crosslink on contact with tissue into a stable gel that fills and conforms to the defect contour. The gel sets in place as part of the injection itself, requiring no external preparation or pre-processing.

What results is a three-dimensional structural matrix — scaffolding into which the patient's own bone marrow progenitor cells can migrate. Over the weeks and months that follow, those cells colonise the scaffold and begin building repair tissue within the defect. The clinical term for this process is acellular matrix-induced chondrogenesis: scaffold-driven cartilage repair that relies entirely on the patient's own biology, with no transplanted cells involved at any stage.

The repair timeline is biological, not immediate. Evidence from published series indicates that structural improvement develops over 12 to 24 months as the progenitor cells mature within the matrix. Patients should expect a gradual shift in function rather than rapid pain relief, and the initial period of protected weight-bearing forms part of the treatment design — it gives the settling scaffold the mechanical conditions it needs.

Accurate image guidance at the point of placement ensures the scaffold is deposited into the defect rather than dispersed into the surrounding joint space, which is particularly relevant given the constrained anatomy of the talar dome.

Which ankle lesions are suitable for ChondroFiller injection

Suitability rests on a few well-defined characteristics rather than a single test result. The most appropriate candidates have a focal, contained defect on the medial or lateral talar dome — a discrete lesion with reasonably preserved surrounding cartilage and without significant collapse of the subchondral bone beneath it. The scaffold needs a structural boundary to fill; diffuse, multi-focal degeneration does not provide one.

Lesion size, established in clinical data as the sharpest predictor of standard treatment failure, also defines where injectable scaffold therapy adds most value. Patients with lesions at or above the 15 mm / 150 mm² threshold — precisely the group for whom bone marrow stimulation alone underperforms — are strong candidates for this approach. The threshold is less a contraindication than a pointer toward which patients stand to gain most from a scaffold that actively supports biological repair rather than relying on the bone marrow's unaided response.

In terms of clinical history, patients who have completed a reasonable course of conservative management — typically three to six months of physiotherapy, bracing, and activity modification — without adequate improvement represent the most common referral. Chronicity alone is not a disqualifying factor; patients with long-standing lesions who have not yet undergone surgery remain within the indication, provided the defect retains appropriate containment. What falls clearly outside it is widespread ankle osteoarthritis, prominent subchondral cyst extension undermining structural support, or the presence of loose bodies that would need addressing independently.

What the clinical evidence currently shows

Three bodies of evidence bear directly on ChondroFiller injection at the ankle. Together — including where they point to a gap — they give the clearest current picture of what to expect.

Syed et al. (2025, Journal of Foot and Ankle Surgery: Asia Pacific) characterised ChondroFiller application for talar osteochondral lesions as single-stage, cell-free matrix implantation enabling regenerative and effective treatment of cartilage injury. As a case series, it establishes feasibility and early outcomes rather than superiority over alternatives.

A separately conducted multicentre randomised study provides stronger design-level evidence: in trial populations, patients showed statistically significant IKDC score improvements at three, six, and twelve months post-treatment. MRI at 52 weeks confirmed scaffold fill at the defect site — structural corroboration that the injected matrix integrates rather than disperses into the surrounding joint. The study is cited across multiple UK clinical centres as part of the evidence base supporting ChondroFiller's CE-mark Class III device approval. A 2026 retrospective series of autologous collagen-induced chondrogenesis (ACIC) — an all-arthroscopic injectable collagen scaffold combined with microfracture — adds ankle-specific outcomes data for the injectable scaffold approach in a different delivery configuration.

Comparator data from the broader biologic augmentation literature help locate these results. A meta-analysis of five studies involving 348 patients found that adding mesenchymal stem cell injection to microfracture produced mean AOFAS scores of 81.5 versus 68.2 for microfracture alone, and MOCART cartilage repair scores of 74.3 versus 63.9 — differences that exceed the minimum clinically important difference at roughly 36-month follow-up. The biologic differs from ChondroFiller, but the structural finding is consistent across the literature: augmenting bone marrow stimulation with any biologic consistently outperforms the unaided procedure. ChondroFiller operates within that same augmentation rationale.

The key evidence gap sits at the frontier rather than the centre of this picture. A 2026 systematic scoping review of eleven ankle cell and scaffold studies found that nine co-administered biologics alongside therapeutic surgery, making it methodologically difficult to isolate the standalone injectable scaffold effect. Controlled trial data specifically for the ultrasound-guided, non-surgical injection route are still accumulating — the current edge of an evidence base that is expanding, not stalled.

Getting assessed for ChondroFiller injection in London

An assessment begins with imaging. Patients who already hold an MRI report should bring it to their first appointment; if the scan is older than twelve months or was performed at low field strength, a repeat may be recommended before any decision is made. The consulting clinician will review lesion size, containment, subchondral bone integrity, and the extent of surrounding cartilage — the same characteristics that determine suitability for the injection pathway discussed in the previous section.

Technique precision at the time of injection matters in practice. Because scaffold placement under ultrasound guidance requires both anatomical familiarity and product-specific training, outcomes are partly a function of clinical experience with the procedure itself — not only lesion biology.

Liquid Cartilage™ (ChondroFiller injection) is delivered in the UK at the London Cartilage Clinic on Harley Street, the country's certified centre for the product. Appointments and further information are available at londoncartilage.com.

1. [1] Implantation of ChondroFiller Liquid® as a Scaffold Material for Chondral Lesions of the Knee. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
3. [3] Cell-Based Therapies for Post-Traumatic Ankle OA and OCLT: Systematic Scoping Review (2026). (2026). https://doi.org/10.3390/bioengineering13070843 https://doi.org/10.3390/bioengineering13070843